KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Change in Account Payables (2020 - 2025)

Recursion Pharmaceuticals' Change in Account Payables history spans 6 years, with the latest figure at $4.4 million for Q4 2025.

  • For Q4 2025, Change in Account Payables fell 45.59% year-over-year to $4.4 million; the TTM value through Dec 2025 reached -$2.6 million, down 140.65%, while the annual FY2025 figure was -$2.6 million, 140.65% down from the prior year.
  • Change in Account Payables reached $4.4 million in Q4 2025 per RXRX's latest filing, up from -$5.9 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $8.1 million in Q4 2024 to a low of -$5.9 million in Q3 2025.
  • Average Change in Account Payables over 5 years is $317200.0, with a median of $383000.0 recorded in 2021.
  • Peak YoY movement for Change in Account Payables: surged 5790.91% in 2021, then plummeted 1488.73% in 2022.
  • A 5-year view of Change in Account Payables shows it stood at -$3.5 million in 2021, then skyrocketed by 119.82% to $695000.0 in 2022, then crashed by 145.61% to -$317000.0 in 2023, then soared by 2662.15% to $8.1 million in 2024, then plummeted by 45.59% to $4.4 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Change in Account Payables are $4.4 million (Q4 2025), -$5.9 million (Q3 2025), and -$4.8 million (Q2 2025).